Buchumschlag

Long non-coding RNAs as a biomarker for homologous recombination deficiency and parp inhibitor sensitivity in high-grade serous ovarian cancers

Homologous recombination deficiency (HRD) and sensitivity to PARP inhibitors are key determinants of therapeutic response in high-grade serous ovarian cancer (HGSC), yet predictive biomarkers beyond BRCA1/2 mutations or genomic HRD scores remain inadequate. Here, we investigate the potential of long...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Doberstein, Kai (VerfasserIn) , Panther, Johannes (VerfasserIn) , Hahnen, Eric (VerfasserIn) , Richters, Lisa (VerfasserIn) , Schouten, Philip (VerfasserIn) , Harter, Philipp (VerfasserIn) , Heitz, Florian (VerfasserIn) , Kommoss, Stefan (VerfasserIn) , Berlit, Sebastian (VerfasserIn) , Tuschy, Benjamin (VerfasserIn) , Sütterlin, Marc (VerfasserIn) , Marmé, Frederik (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 01 October 2025
In: Communications biology
Year: 2025, Jahrgang: 8, Pages: 1-17
ISSN:2399-3642
DOI:10.1038/s42003-025-08836-9
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s42003-025-08836-9
Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s42003-025-08836-9
Volltext
Verfasserangaben:Kai Doberstein, Johannes Panther, Eric Hahnen, Lisa Richters, Philip C. Schouten, Philipp Harter, Florian Heitz, Stefan Kommoss, Sebastian Berlit, Benjamin Tuschy, Marc Sütterlin & Frederik Marmé
Beschreibung
Zusammenfassung:Homologous recombination deficiency (HRD) and sensitivity to PARP inhibitors are key determinants of therapeutic response in high-grade serous ovarian cancer (HGSC), yet predictive biomarkers beyond BRCA1/2 mutations or genomic HRD scores remain inadequate. Here, we investigate the potential of long non-coding RNAs (lncRNAs) as predictive markers of HRD and PARP inhibitor response. We identify a panel of lncRNAs that stratifies HGSC tumors by HRD status and drug sensitivity. Among these, ENSG00000272172.1 is significantly upregulated in HRD-positive tumors and is detectable in both formalin-fixed tissue and plasma, supporting its use as a minimally invasive biomarker. Functional analyses reveal that this lncRNA contributes to genome stability by modulating replication dynamics. These findings highlight a previously unrecognized role for lncRNAs in the HRD phenotype and suggest translational potential for ENSG00000272172.1 in guiding clinical decision-making.
Beschreibung:Gesehen am 18.12.2025
Beschreibung:Online Resource
ISSN:2399-3642
DOI:10.1038/s42003-025-08836-9

Ähnliche Einträge